We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OGT and Emory Genetics Laboratory Develop New Molecular Arrays
Product News

OGT and Emory Genetics Laboratory Develop New Molecular Arrays

OGT and Emory Genetics Laboratory Develop New Molecular Arrays
Product News

OGT and Emory Genetics Laboratory Develop New Molecular Arrays


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "OGT and Emory Genetics Laboratory Develop New Molecular Arrays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT) has expanded its range of research-validated CytoSure Molecular Arrays to investigate DNA copy number variation (CNV) underlying a variety of genetic disorders.

Designed and optimized in collaboration with experts at Emory Genetics Laboratory (EGL; Atlanta, USA), the arrays are the ideal complement to DNA sequencing, providing a particularly powerful tool for investigating the variety of aberrations underlying genetic disorders.

Professor Madhuri Hegde, Professor of Human Genetics at Emory University School of Medicine, will discuss the design and application of these arrays at the American College of Medical Genetics (ACMG) meeting on Thursday 27 March 2014.

Comparative genomic hybridization arrays (aCGH) are the gold-standard for CNV detection and the 60-mer oligonucleotide probes utilized by OGT’s aCGH platform have been shown to deliver superior CNV detection than alternative platforms.

The expanded CytoSure Molecular Array portfolio now enables detection of CNV in genes associated with over 20 genetic disorders, including cardiovascular, inherited eye, intellectual disability and neuromuscular disorders, as well as a range of inherited cancers.

In addition, genes covering each disorder can be combined to create bespoke custom arrays, or further customized by the addition of novel content to suit each individual research project.

For the easy extraction of meaningful results from aCGH data, all CytoSure Molecular Arrays are supplied with OGT’s class-leading CytoSure Interpret Software.

Utilizing highly targeted, exon-focussed arrays has been shown to detect CNVs as small as 12 bp in size that were missed by targeted NGS.

Whether used alone or alongside sequencing, CytoSure Molecular Arrays allow researchers to reliably investigate the role of CNV in a wide range of genetic disorders.

Advertisement